Biomarkers Predictive for In-Hospital Mortality in Patients with Diabetes Mellitus and Prediabetes Hospitalized for COVID-19 in Austria: An Analysis of COVID-19 in Diabetes Registry

Viruses

Thomas Stulnig¹  Slobodan Peric¹  Andreas Zitterl¹  Erich Pawelka²  Mario Karolyi²  for the COVID-19 in Diabetes in Austria³  Caren Sourij⁴  Peter Wolf⁵  Alexandra Kautzky-Willer⁵  Christian Ciardi⁶  Carmen Klammer⁷  Martin Clodi⁷  Othmar Moser⁸  Claudia Ress⁹  Susanne Kaser⁹  Lars Stechemesser^1,10  Harald Stingl^1,11  Michael Wagner^1,11  Christian Schelkshorn^1,12  Norbert Tripolt^1,13  Hannah Stöcher^1,13  Felix Aberer^1,13  Oliver Malle^1,13  Harald Sourij^1,13  Faisal Aziz^1,13  Alexander Bräuer^1,14  Peter Fasching^1,14 

[1] 3rd Department and Karl Landsteiner, Institute for Metabolic Diseases and Nephrology, Clinic Hietzing, Vienna Health Care Group, 1130 Vienna, Austria;4th Medical Division with Infectiology, SMZ Süd–KFJ-Hospital Vienna, 1100 Vienna, Austria;;Clinical Division for Cardiology, Medical University Graz, 8036 Graz, Austria;Clinical Division for Endocrinology and Diabetology and Metabolic Diseases, AKH Vienna, 1090 Vienna, Austria;Clinical Division for Internal Medicine, Endocrinology, Diabetology and Metabolic Diseases, St. Vinzenz Hospital Zams, 6511 Zams, Austria;Clinical Division for Internal Medicine, Konventhospital Barmherzige Brüder Linz, 4020 Linz, Austria;Department for Exercise Physiology & Metabolism, University of Bayreuth, 95445 Bayreuth, Germany;Department for Internal Medicine I, Medical University Innsbruck, 6020 Innsbruck, Austria;Department for Internal Medicine I, Paracelsus Medical University, 5020 Salzburg, Austria;Division for Internal Medicine, Hospital Melk, 3390 Melk, Austria;Division for Internal Medicine, Hospital Stockerau, 2000 Stockerau, Austria;Interdisciplinary Metabolic Medicine Trials Unit, Department of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria;Medical Division for Endocrinology, Rheumatology and Acute Geriatrics, Wilhelminen Hospital Vienna, 1160 Vienna, Austria;

关键词: COVID-19;    SARS-CoV-2;    diabetes mellitus;    biomarker;   

DOI  :  10.3390/v14061285

来源: DOAJ

【 摘 要 】

Background: This study assessed the predictive performance of inflammatory, hepatic, coagulation, and cardiac biomarkers in patients with prediabetes and diabetes mellitus hospitalized for COVID-19 in Austria. Methods: This was an analysis of a multicenter cohort study of 747 patients with diabetes mellitus or prediabetes hospitalized for COVID-19 in 11 hospitals in Austria. The primary outcome of this study was in-hospital mortality. The predictor variables included demographic characteristics, clinical parameters, comorbidities, use of medication, disease severity, and laboratory measurements of biomarkers. The association between biomarkers and in-hospital mortality was assessed using simple and multiple logistic regression analyses. The predictive performance of biomarkers was assessed using discrimination and calibration. Results: In our analysis, 70.8% had type 2 diabetes mellitus, 5.8% had type 1 diabetes mellitus, 14.9% had prediabetes, and 8.6% had other types of diabetes mellitus. The mean age was 70.3 ± 13.3 years, and 69.3% of patients were men. A total of 19.0% of patients died in the hospital. In multiple logistic regression analysis, LDH, CRP, IL-6, PCT, AST-ALT ratio, NT-proBNP, and Troponin T were significantly associated with in-hospital mortality. The discrimination of NT-proBNP was 74%, and that of Troponin T was 81%. The calibration of NT-proBNP was adequate (p = 0.302), while it was inadequate for Troponin T (p = 0.010). Conclusion: Troponin T showed excellent predictive performance, while NT-proBNP showed good predictive performance for assessing in-hospital mortality in patients with diabetes mellitus hospitalized with COVID-19. Therefore, these cardiac biomarkers may be used for prognostication of COVID-19 patients.

【 授权许可】

Unknown